Enlivex Therapeutics Ltd. (ENLV) |
| 0.8382 -0.123 (-12.82%) 04-13 16:00 |
| Open: | 0.8749 |
| High: | 0.9137 |
| Low: | 0.741 |
| Volume: | 1,827,124 |
| Market Cap: | 20(M) |
| PE Ratio: | 0.03 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.32 |
| Resistance 1: | 1.10 |
| Pivot price: | 0.98 |
| Support 1: | 0.74 |
| Support 2: | 0.62 |
| 52w High: | 2.1 |
| 52w Low: | 0.66 |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Financials
| EPS | 25.480 |
| Book Value | 8.150 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -0.8 |
| Return on Equity (ttm) | 126.2 |
Company news
Sat, 11 Apr 2026
If You Invested $1,000 in Enlivex Ltd (ENLV) - Stock Titan
Thu, 09 Apr 2026
ENLV SEC Filings - Enlivex Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 03 Apr 2026
ENLV PE Ratio & Valuation, Is ENLV Overvalued - Intellectia AI
Mon, 23 Feb 2026
Enlivex Rebrands as Enlivex Ltd. Following Shareholder Approval - TipRanks
Fri, 23 Jan 2026
Enlivex Therapeutics to delist from Tel Aviv Stock Exchange in April - Investing.com
Mon, 12 Jan 2026
ENLV: Analyst Raises Price Target Significantly | ENLV Stock New - GuruFocus
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
